...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Schizophrenia relapse, patient considerations, and potential role of lurasidone
【24h】

Schizophrenia relapse, patient considerations, and potential role of lurasidone

机译：精神分裂症复发，患者考虑因素以及卢拉西酮的潜在作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

When treating persons with schizophrenia, delaying time to relapse is a main goal. Antipsychotic medication has been the primary treatment approach, and there are a variety of different choices available. Lurasidone is a second-generation (atypical) antipsychotic agent that is approved for the treatment of schizophrenia and bipolar depression. Three long-term studies of lurasidone have examined time to relapse in persons with schizophrenia, including a classic placebo-controlled randomized withdrawal study and two 12-month active comparator studies (vs risperidone and vs quetiapine extended-release). Lurasidone 40–80 mg/d evidenced superiority over placebo (number needed to treat [NNT] vs placebo for relapse, 9). Lurasidone 40–160 mg/d was noninferior to quetiapine extended-release 200–800 mg/d on the outcome of relapse, and was superior on the outcome of avoidance of hospitalization (NNT 8) and the outcome of remission (NNT 7). Lurasidone demonstrated a lower risk for long-term weight gain than the active comparators. Demonstrated differences in tolerability profiles among the different choices of antipsychotics make it possible to attempt to match up an individual patient to the best choice for such patient based on past history of tolerability, comorbidities, and personal preferences, potentially improving adherence.
机译：当治疗精神分裂症患者时，延迟复发时间是主要目标。抗精神病药物一直是主要的治疗方法，并且有多种不同的选择。卢拉西酮是第二代（非典型）抗精神病药，已被批准用于治疗精神分裂症和双相抑郁症。卢拉西酮的三项长期研究检查了精神分裂症患者的复发时间，包括经典的安慰剂对照的随机戒断研究和两项为期12个月的主动比较研究（与利培酮和喹硫平缓释相比）。卢拉西酮40-80 mg / d证明优于安慰剂（治疗[NNT]相对于安慰剂复发所需的数字，9）。卢拉西酮40-160 mg / d在复发方面不逊于喹硫平缓释200-800 mg / d，在避免住院的结果（NNT 8）和缓解的结果（NNT 7）方面优于喹硫平缓释200-800 mg / d。卢拉西酮证明长期体重增加的危险性低于活性比较剂。在不同的抗精神病药物选择之间表现出的耐受性差异表明，可以根据过去的耐受性，合并症和个人喜好，尝试将单个患者与该患者的最佳选择进行匹配，从而可能会提高依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号